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New aspects in the biology of cutaneous
B-cell lymphomas
Immunologic and molecular genetic studies greatly contributed to a
better understanding and interpretation of the distinct clinico-patho-
logic features of primary cutaneous B-cell lymphomas (CBCL), which
are the basis for the consensus WHO-EORTC classification. There is
increasingly accumulating evidence that these well defined clinico-
pathologic entities of CBCL have specific immunologic and molecular
features, which further support their nosologic categorization as well as
either interesting similarities with other extranodal B-cell lymphomas
or definite peculiarities as compared to nodal B-cell lymphomas of
similar histotype (specifically, follicle center lymphoma and diffuse large
B-cell lymphoma).
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The topic of primary cutaneous B-cell lymphomas
(CBCL) in terms of diagnosis, classification, and
historical perspective is extensively dealt with in
another article of this JCP issue. As a general com-
ment, the immunologic and molecular research in
the field of CBCL considerably contributed–in addi-
tion to careful clinico-pathologic studies–to the cat-
egorization of these lymphomas first proposed in the
EORTC classification1 and recently recognized in
the consensus WHO-EORTC classification.2
At present, there are many unanswered questions
concerning the biology of CBCL and, more in gen-
eral, of the homing of B cells into the skin and their
predilection to stay localized and to proliferate in
the skin in many instances. In fact, there still is no
consistent information concerning the existence of a
B-cell arm of the skin immune system. In the skin,
there are no known equivalents to the Peyer’s
patches of the intestine or the Waldeyer’s ring of
the pharynx. In addition, different from T cells, B
cells are not found in normal human skin.
Currently, the only data concern the demonstration
that sweat and sebaceous glands synthesize the
secretory component of dimeric immunoglobulin
(Ig)A in humans.3 Indeed, a possible speculation is
that the skin and draining lymph nodes form an
integrated system whereby a lymphoproliferative
response to antigenic stimuli may be elicited in the
skin.4 In addition, it has been hypothesized that the
expression of skin-specific homing receptors by nor-
mal and/or neoplastic B lymphocytes in specific
situations may explain the preferential circulation
to and accumulation in the skin of lymphoid B
cells. Another possibility is that a combination of
etiological factors–infectious, immunologic, and
genetic–may play a role in the development of lym-
phoproliferative B-cell disorders of the skin.
As a matter of fact, several antigenic stimuli are
known to eventuate into a reactive B-cell response.
These reactions, variously defined as cutaneous
lymphoid hyperplasia, pseudo-B-cell lymphoma
(P-CBCL), or lymphadenosis benigna cutis, may be
caused by insect bites, in particular tick bites trans-
mitting a Borrelia burgdorferi infection, acupuncture,
antigen injections (drug eruptions, vaccinations, spe-
cific immune therapy), and tattoo pigments among
others.5 Borrelia burgdorferi infection6–8 and tattoo pig-
ments9,10 have also been suggested to be involved in
the development of CBCL, in particular marginal-
zone B-cell lymphomas. Interestingly, B. burgdorferi-
specific DNA sequences have been demonstrated in
a significant minority of CBCL from European areas
with endemic Borrelia infections6,7 but could not be
detected in CBCL from different areas in the United
States11 and Asia.12 Different from Borrelia infection,
no viral DNA sequences have been found in CBCL.13
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Accumulating evidences suggest that these indolent
CBCL ( pcMZL, primary cutaneous marginal zone
lymphoma; pcFCL, primary cutaneous follicle center
lymphoma) and P-CBCL represent indeed a spectrum
of cutaneous B-cell lymphoproliferative disorders with
a step-wise progression from a reactive to a neoplastic
state.10,14 This also explains why it can be so difficult
to differentiate early stages of these indolent CBCL
from P-CBCL. Apart from clinico-pathologic simila-
rities and the above-mentioned shared association
with Borrelia infection and tattoo pigments, clonal Ig
gene rearrangements have been demonstrated not
only in CBCL but also in a proportion of P-CBCL,
as defined by immunohistochemical criteria.10,15
Interestingly, molecular analysis of CBCL recently
documented intraclonal diversity with a high degree
of somatic mutations, supporting the hypothesis of an
antigen-driven process arising from transformed
germinal-center B cells.16
Another intriguing approach to the biology of
CBCL concerns the expression of chemokines (che-
moattractanct cytokines), especially those regulating
the localization of lymphoid cells during lymphopoi-
esis, antigen priming, and immune surveillance,
referred to as ‘‘housekeeping’’ (rev. in 17). In fact, it
has been demonstrated that both BCA-1 (also
regarded as CXCL13, the most effective B-cell che-
moattractant) and CXCR5 (a chemokine receptor
with predominant expression on blood and tonsillar
B cells, as well as on a subset of memory CD4þ T-
cells) are highly expressed in Helicobacter pylori (HP)-
induced mucosa-associated lymphoid tissue (MALT)
lymphoma with a distinctive pattern of expression,18
thus suggesting a possible pathogenic role of BCA-1 in
the natural history of MALT lymphoma. We have
recently investigated the possible involvement of
BCA-1 and CXCR5 in the pathogenesis of CBCL
and P-CBCL.19 First of all, no BCA-1 or CXCR5
expression was found at the immunohistochemical
and molecular level in either clinically healthy skin
or CTCL, thus confirming the B-cell-restricted speci-
ficity of these chemokines. The significant differences
found between P-CBCL and indolent CBCL, mar-
ginal-zone lymphoma (MZL) type (CD35þ/BCA-1þ
dendritic cells found in lymphoid follicles of P-CBCL
only; in CBCL virtually no CD35þ dendritic cells
coexpressing BCA-1, with intensity of CXCR5
expression on CD22þ B cells lower than that of
BCA-1),19 are in keeping with those evidenced in
HP-induced MALT (gastritis) and gastric lymphoma,
MALT type.18 In fact, the distribution and intensity of
BCA-1 and CXCR5 in (secondary) lymphoid follicles
of P-CBCL and indolent CBCL, MZL type parallel
those found in HP-induced MALT (gastritis) and in
gastric lymphoma, respectively. These findings add a
further element to the close similarities between
CBCL, MZL type, and MALT lymphoma, with
chronic antigen stimulation as a possible common
pathogenic denominator.18,19
There is no doubt that immunologic and mole-
cular genetic studies greatly contributed to a better
understanding and interpretation of the distinct
clinico-patholgic features of CBCL, which are the
basis for the EORTC1 and the consensus WHO-
EORTC classifications.2 Primary cutaneous MZL
(pcMZL) neoplastic cells characteristically express
bcl-2 protein and are negative for bcl-6, which is a
very useful additional criterion to differentiate
pcMZL from primary cutaneous follicle-center lym-
phoma (pcFCL).20,21 Recent studies show the pre-
sence of the t(14;18)(q32;q21) involving the IGH
gene on chromosome 14 and the MLT gene on
chromosome 18 in a proportion of pcMZL.22,23
Other translocations observed in gastric MALT
lymphomas as well as other extranodal MZL, such
as t(11;18)(q21;q21) and t(1;14)(p22;q32), have not
been found in pcMZL.23,25 pcFCL consistently express
bcl-6,20,21,26,27 whereas they–unlike nodal and sec-
ondary cutaneous follicular lymphomas–do not
express bcl-2 protein or show faint bcl-2 staining in
a minority of neoplastic B cells.27–30 Staining for
MUM-1/IRF4 is negative.31,32 Somatic hypermuta-
tion of variable heavy and light chain genes has
been demonstrated, which further supports the
follicle-center-cell origin of these lymphomas.16,33
In most studies, pcFCL, including cases with a folli-
cular growth pattern, do not show the t(14;18),
which is characteristically found in systemic follicu-
lar lymphomas and a proportion of systemic diffuse
large B-cell lymphomas.29,33,34 Inactivation of p15
and p16 tumor-suppressor genes by promotor
hypermethylation has been reported in a relatively
small proportion of pcFCL.35 In a recent study using
interphase fluorescence in situ hybridization, no
evidence for translocations involving IgH, myc, or
bcl-6 loci were found.25 pcFCL have the gene
expression profile of germinal center-like large
B-cell lymphomas.31,32 In contrast to the group of
pcFCL, primary cutaneous large B-cell lymphoma,
leg type (pcLBCL-LT) show strong bcl-2 expression,
also in the much less-frequent cases not located on
the legs.21,29,36 Different from pcFCL, most
pcLBCL-LT express MUM-1/IRF4 protein.31,32
The t(14;18) is not found in pcLBCL, although
strong bcl-2 expression is common in this
group.29,37 In some cases, bcl-2 overexpression
may result from chromosomal amplification of the
bcl-2 gene.37 Inactivation of p15 and p16 tumor-
suppressor genes by promotor hypermethylation
has been detected in a variable proportion of
pcLBCL-LT.35 Chromosomal imbalances have
been identified in most pcLBCL-LT, with gains in
18q and 7p and loss of 6q as most common find-
ings.37–39 Recent reports showed translocations
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involving myc, bcl-6, and IgH genes in most pcLBCL-
LT but not in patients with pcFCL with a diffuse
infiltration of large centrocytes.25 Finally, recent
studies suggest that pcLBCL-LT have an activated
B-cell gene expression profile, in parallel with
MUM-1/IRF4 protein expression.31,32
In conclusion, there is increasingly accumulating
evidence that the well defined clinico-pathologic
entities of CBCL have specific immunologic and
molecular features, which further support their
nosologic categorization as well as either interesting
similarities with other extranodal B-cell lymphomas
or definite peculiarities as compared to nodal B-cell
lymphomas of similar histotype (specifically, follicle
center lymphoma and diffuse large B-cell
lymphoma).
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